



# MARKET RELEASE

17 August 2017

**Botanix Pharmaceuticals Limited**

## **TRADING HALT**

The securities of Botanix Pharmaceuticals Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Monday 21 August 2017 or when the announcement is released to the market.

Security Code:           BOT

Hayley Pratt

**ADVISER, LISTINGS COMPLIANCE (PERTH)**

17 August 2017

The Manager  
Australian Securities Exchange  
152-158 St Georges Terrace  
PERTH WA 6000

TradingHaltsPerth@asx.com.au

Attention: Sandra Wutete

Via email

Dear Sirs,

#### REQUEST FOR A TRADING HALT

Pursuant to ASX Listing Rule 17.1, Botanix Pharmaceuticals Limited (ASX:BOT) (Company) requests a trading halt of its securities from ASX with effect from commencement of trading on Thursday 17 August 2017.

In accordance with ASX Listing Rule 17.1, the Company provides the following information regarding this request:

1. The reason for the trading halt is that the Company intends to make an announcement regarding ethics approval for its BTX 1503 acne patient study.
2. The Company requests that the trading halt continue until the earlier of commencement of trading on Monday 21 August 2017 or when the announcement referred to in paragraph 1 is released to the market.
3. The Company expects the event which will end the trading halt is the announcement referred to in paragraph 1.

The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely



Simon Robertson  
Company Secretary